{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "amend_06",
        "affectedSection": "Section 1: Synopsis; Section 4.4: Duration of the Study",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Extension of Part B open-label duration from 1 year to 2 years following Last Patient Out from Part A."
      },
      {
        "id": "impact_2",
        "amendmentId": "amend_06",
        "affectedSection": "Section 1: Synopsis; Section 6.1.6; Section 10.10: Appendix J",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Introduction of home infusion facilities for patients in preselected countries."
      },
      {
        "id": "impact_3",
        "amendmentId": "amend_06",
        "affectedSection": "Section 3.2; Section 3.5; Section 4.3.8; Section 7.7",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Addition of immunogenicity (ADA) as a new exploratory objective and endpoint."
      },
      {
        "id": "impact_4",
        "amendmentId": "amend_06",
        "affectedSection": "Section 10.1: Appendix A",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Correction of clinical laboratory evaluations by removing specific parameters."
      },
      {
        "id": "impact_5",
        "amendmentId": "amend_06",
        "affectedSection": "Throughout Document",
        "impactLevel": "Administrative",
        "instanceType": "StudyAmendmentImpact",
        "description": "Replacement of statistical terminology (ITT to FAS) and alignment with Sanofi documentation standards."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "amend_06",
        "reasonText": "Gather more evidence on long-term safety, tolerability and durability of response of BIVV009.",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "amend_06",
        "reasonText": "Evaluate the safety and patient satisfaction with the convenience of home infusion.",
        "category": "Operational",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "amend_06",
        "reasonText": "Help characterize immunogenicity of BIVV009.",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_4",
        "amendmentId": "amend_06",
        "reasonText": "Comply with Sanofi standards and provide clarification of clinical laboratory evaluations.",
        "category": "Administrative",
        "isPrimary": false,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "amend_06",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "1.0",
        "beforeText": "1 year following last patient out (LPO) under Part A",
        "afterText": "2 years following last patient out (LPO) under Part A",
        "summary": "Extended Part B duration."
      },
      {
        "id": "change_2",
        "amendmentId": "amend_06",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "1.0",
        "beforeText": "Intent to treat (ITT)",
        "afterText": "Full Analysis Set (FAS)",
        "summary": "Updated statistical analysis set terminology."
      },
      {
        "id": "change_3",
        "amendmentId": "amend_06",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "3.5",
        "afterText": "Exploratory Objectives were added for Part B to describe the safety and patient satisfaction with the convenience of home infusion and to evaluate the immunogenicity of BIVV009.",
        "summary": "Added new exploratory objectives for the extension phase."
      },
      {
        "id": "change_4",
        "amendmentId": "amend_06",
        "changeType": "Deletion",
        "instanceType": "StudyChange",
        "sectionNumber": "10.1",
        "beforeText": "Iron",
        "summary": "Removed Iron from the clinical chemistry panel in Appendix A."
      },
      {
        "id": "change_5",
        "amendmentId": "amend_06",
        "changeType": "Clarification",
        "instanceType": "StudyChange",
        "sectionNumber": "6.1.1.1",
        "afterText": "Revaccination with booster doses should be given according to regional guidelines for patients with persistent complement deficiency.",
        "summary": "Clarified vaccination requirements for encapsulated bacterial pathogens."
      },
      {
        "id": "change_6",
        "amendmentId": "amend_06",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "6.1.5.2",
        "afterText": "Hematology panel (beginning at Week 79) and Clinical chemistry panel (beginning at Week 79)",
        "summary": "Added assessment frequency for the second year of Part B."
      }
    ],
    "summary": {
      "impactCount": 5,
      "reasonCount": 4,
      "changeCount": 6
    }
  }
}